CD8A and breast cancer: In two breast cancer models, PD-1 blockade combined with poly-IC efficiently modulates immune cell profiles, such as increase in CD8+ T cells, type-1 conventional DCs, immunogenic M1 macrophages and CD169+ macrophages, and reduction in MDSC, plasmacytoid DCs, regulatory T cells and immunotolerant M2 macrophages, which in turn eliminates not only the primary tumor, but also metastasis [158].